|
Match
|
Document |
Document Title |
|
|
7384640 |
Mutant cholera holotoxin as an adjuvant
A mutant cholera holotoxin featuring a point mutation at amino acid 29 of the A subunit, wherein the glutamic acid residue is replaced by an amino acid other than aspartic acid, is useful as an...
|
|
|
7364745 |
Development of a live, attenuated, recombinant vaccine for Brucellosis
A recombinant, attenuated strain of Brucella suis or Brucella melitensis with a deficiency in carboxyl-terminal protease activity or tail-specific protease activity can be used as a vaccine for...
|
|
|
7118739 |
Biocontrol of plant diseases caused by Fusarium species with novel isolates of Pantoea agglomerans
Microbiological agents are provided for control of certain diseases of wheat and other cereals caused by Fusarium species, including Fusarium head blight of wheat and other cereals. These...
|
|
|
7041296 |
Methods of treating inflammatory bowel disease using cholera toxin B subunit
The present invention provides a method of treating or preventing inflammation in a subject, comprising administering to the subject an effective amount of cholera toxin subunit B. The present...
|
|
|
6991793 |
Method of protecting fish against columnaris disease with modified live Flavobacterium columnare
Safe and effective live vaccines against Flavobacterium columnare of fish were created through the induction of rifampicin resistance in a native Flavobacterium columnare isolate; these...
|
|
|
6811787 |
Over-expressing homologous antigen vaccine and a method of making the same
This invention relates to an over-expressing homologous antigen vaccine, a method of producing the same, and use of the vaccine for prophylaxis or treatment of vertebrates at risk of or suffering...
|
|
|
6599509 |
Compositions and methods comprising helicobacter antigens for treatment and prevention of inflammatory bowel disease
The treatment of IBD in mammals, including humans, is described. More particularly, the present invention relates to compositions and methods for the treatment of IBD associated with Helicobacter...
|
|
|
6582699 |
Combination vaccine for enhancing immunity against brucellosis
A vaccine comprising a combination of Brucella “A” and “M” outer-polysaccharides (OPSs) and “R” protein antigens for enhancing immunity against brucellosis is disclosed. The OPS may be...
|
|
|
6444210 |
Bacterial and synthetic polysaccharide immunomodulators that enhance general immunity
The present invention relates to the effects of bacterial polysaccharides on cell mediated immunity in animals. Polysaccharides of the present invention comprise the outer polysaccharides (OPS)...
|
|
|
6444445 |
Live vaccine against Brucellosis
Live Brucella vaccines and methods for preparing the live vaccines protective against brucellosis are described. The vaccines are prepared by introducing a deletion in the rfbU gene of a strain of...
|
|
|
6436652 |
Method of detecting a pathogen using a virus
A bacteriophage linked to an enzyme can replace an antibody in a system for detecting the presence of a bacteria in a sample. Specifically Brucella abortus (a pathogen which causes brucellosis in...
|
|
|
6296855 |
17-KDA Brucella abortus antigen, recombinant polypeptides, nucleic acids coding for the same and use thereof in diagnostic and prophylactic methods and kits
The present invention relates to an isolated 17-kDa Brucclla antigen characterized by an amino acid sequence having at least 60% homology, preferably at least 70% homology, more preferably having...
|
|
|
6277379 |
Use of purified invaplex from gram negative bacteria as a vaccine
A novel composition comprising Invaplex from gram-negative bacteria is described and is effective as a vaccine against gram-negative bacterial infection.
|
|
|
6221386 |
Use of virulence factors of pathogens to improve liposomal delivery of therapeutic agents
Liposome encapsulated antibiotic therapy has limited application against infectious organisms, which can sequester in non-phagocytic cells. Virulence factors of these infectious organisms, for...
|
|
|
6203799 |
Vibrio cholerae mutants which are soft-agar penetration defective and lack a functional CtxA subunit
V. cholerae vaccine strains which have a soft agar penetration-defective phenotype and methods for making such strains are described. Also described are methods for identifying new genes involved...
|
|
|
5997881 |
Method of making non-pyrogenic lipopolysaccharide or A
The present invention provides gram-negative bacterial strains that produce substantially pure non-pyrogenic lipopolysaccharide or lipid A. The present invention also relates to a use of said...
|
|
|
5951987 |
Polysaccharide vaccine to enhance immunity against brucellosis
A vaccine comprising purified outer-polysaccharide (OPS) is effective for protection against brucellosis. The vaccine is derived from Brucella or a variety of cross reactive bacteria. The vaccine...
|
|
|
5939075 |
Mutants of Brucella melitensis
The vaccines are prepared by isolating the Brucella genes complementing mutations in the purEK genes of Escherichia coli, physically mapping, determining the DNA sequence, constructing a defined...
|
|
|
5906826 |
Method of inducing an immune response in a young animal
The invention provides a method of priming an immune response in the presence of maternal antibody in a young animal by administering to a 1-90 day old animal, a biocompatible and non-toxic solid...
|
|
|
5858352 |
Vaccine containing a Shigella bacterium having an enhanced antigenic property
Methods using in vitro processes are disclosed for inducing or enhancing expression of enteric bacterial antigens or virulence factors. The methods, therefore, produce antigenically enhanced...
|
|
|
5855894 |
Pasteurella haemolytica type A-1 bacterin-toxoid vaccine
This invention relates to the field of Pasteurella haemolytica vaccines. More particularly, the invention relates to a bacterin-toxoid vaccine capable of inducing immunity in bovine species in one...
|
|
|
5804199 |
Oil-based and water-based adjuvant mixture
The invention relates to a vaccine comprising an antigenic substance and a mixture of two adjuvants wherein one adjuvant is oil-based whereas the other adjuvant is water-based.
|
|
|
5718903 |
Vaccine comprising Brucella abortus which has O polysaccharide antigen absent
The present invention is an improved vaccine against Brucella abortus which permits differentiation between vaccinated and field strain infected cattle. The vaccine can be administered in two...
|
|
|
5006463 |
Immunoassays for discriminating between brucellosis infections and vaccinations
A method is disclosed for discriminating between cattle vaccinated against and those infected with Brucella spp. The method involves immunoassay using a purified polysaccharide containing...
|
|
|
4764370 |
Vaccine utilizing an avirulent strain of Salmonella typhimurium
A vaccine against a microbial pathogen comprised of a live, immunogenic but prototrophic and avirulent mutant strain of the selected microbial pathogen in an amount effective to confer immunity. A...
|
|
|
4701323 |
Vaccines for counteracting inhibition of neutrophil degranulation
Vaccines for counteracting inhibition of neutrophil degranulation by pathogenic cellular microorganisms comprise one or more purines conjugated to antigenic carriers. The purines include adenine...
|
|
|
4493825 |
Purified and antigenically selective vaccines for domestic animals
Purified antigenically selective vaccines for domestic animals are prepared from microorganism cultures containing the immunizing agent by first complexing the immunizing agent with micro-particles...
|
|
|
4340588 |
Brucellosis vaccine for cattle containing mycolate esters of trehalose
Vaccine utilizing killed Brucella abortus strain 45/20 whole cells is useful for immunizing bovines. The vaccine contains trehalose dimycolate or an analog as an adjuvant.
|
|
|
4152412 |
Marking vaccine
A vaccine, toxoid or like agent is administered to an animal by injecting the agent (usually intracutaneously) on a physiologically acceptable colored particle, preferably activated charcoal, which...
|
|
|
3891751 |
Vaccines and processes for their preparation
Non-agglutinogenic vaccines are prepared containing the desired antigen and sufficient corresponding immune serum to saturate the agglutinogenic sites of the antigen.
|
|
|
3885011 |
Vaccine adjuvants
The immunostimulating action of certain imidazo[2,1-b]thiazoles when used as a vaccine adjuvant.
|
|
|
3515708 |
PROTECTING DOGS AGAINST BRUCELLA CANIS BACTEREMIA WITH KILLED BRUCELLA ABORTUS STRAIN 45/20 VACCINE
|
|
|
3449209 |
METHOD OF PREPARING BRUCELLA ABORTUS VACCINES
|
|
|
3342684 |
Brucellosis antigens
|
|
|
3193460 |
Method and apparatus for culturing micro-organisms
|
|
|
3184384 |
Method of producing brucella abortus vaccine
|
|
|
3097141 |
Immunological method
|
|
|
2958629 |
Preparation of vaccine with brucella killed by patulin compounds
|
|
|
2915437 |
Method of controlling brucellosis
|
|
|
2915438 |
Preparation of brucella antigen
|
|
|
2787576 |
Attenuating b. abortus and p. multocida
|
|
|
3798320 |
Title is not available
|